Why is p53 protein stabilized in neoplasia? some answers but many more questions!

Journal of Pathology

Volumn 184, Issue 4, 1998, Pages 348-350

  Save, Vicki ^a   Nylander, Karin ^b   Hall, Peter A ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Imlm2; KET; P53; P73; Protein protein interaction; protein stability

Indexed keywords

MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; TUMOR PROTEIN;

EDITORIAL; HUMAN; METABOLISM; NEOPLASM;

HUMANS; NEOPLASM PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032038751     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199804)184:4<348::AID-PATH1227>3.0.CO;2-O     Document Type: Article

References (35)

1. Wynford-Thomas D. p53 in tumour pathology: can ve trust immunohistochemistry? J Pathai 1992; 166: 329-330.
2. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry?-revisited! J Palhol 1994; 172: 1 4.
3. Dowcll SP, Derias N, Wilson POG. Lane DP, Hall PA. The clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res 1994; 54: 2914-2918.
4. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. A' Engl J Med 1993; 329: 1318 1327.
5. MacCallum DE. Hupp TR, Midgley CA, el al. The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 1996; 13: 2575-2587.
6. Cruz IB, Snijders PJ, Meijer CJ, el al. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol 1998; 184..
7. Hall PA, Meek D, Lane DP. p53: integrating the complexity. J Patlml 1996: 180: 1 5.
8. Ko LJ. Prives C. p53: puzzle and paradigm. Genes Der 1996; 10: 1054 1072.
9. Levine AJ. p53. the cellular gatekeeper for growth and division. Cell 1997: 88: 323-331.
10. Chen X, Ko LJ, Jayararman L, Prives C. p53 levels, functional domains and DNA damage determine the extent of the apoptotic response of tumo ir cells. Genes Dev 1996; 10: 2438-2451.
11. Lassus P. Ferlin M, Piette J, Hibner U. Anti-apoptotic activity of low levt Is of wild-type p53. EMBO J 1996; 15: 4566-573.
12. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequencespecific DNA binding function of p53. Cell 1995: 83: 237-245.
13. Mosner J. Mummenbrauer T, Bauer C, Sczakiel G, Grosse F. Deppen W. Negative feedback regulation of wild-type p53 biosynthesis. EMBO. F I995; 14: 4442 4449.
14. Fu L, Benchimol S. Participation of the human p53 3'UTR in translations! repression and activation following gamma-irradiation. EMBO J 1997; 1 >: 4117-125.
15. Meek DW. Post-translational modification of p53. Sentin Cancer Bioi 1994; 5: 203-210.
16. Ostermeyer AG, Runko E, Winkfield B, Ahn B. Moll UM. Cytoplasmical y sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptidc. Proc Natl Acad Sei USA 1996; 93: 15 190-15 194.
17. Moll UM. Ostermeyer AG, Haladay R. Winkfield B. Frazier M. Zambe ti G. Cytoplasmic sequestration of wild-tvpe p53 protein impairs the Gl checkpoint after DNA damage. Mol Ceil Biol 1996; 16: 1126-1137.
18. Martinez JD. Craven MT. Joseloff E. Bowden GT. Regulation of DNA binding and transactivation of p53 in nuclear localisation and phosphoryUtion. Oncogene 1997; 14: 2511-2520.
19. Piette J. Neel H, Maréchal V. mdm2: keeping p53 under control. Oncoge.ie 1997: 15: 1001-1010.
20. Chen J. Maréchal V, Levine AJ. Mapping of the p53 and mdm2 interactk n domains. Mol Cell Biol 1993; 13: 4107-1114.
21. Momand J, Zambetti GP. Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
22. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulato-y feedback loop. Genes Dev 1993: 7: 1126-1132.
23. Kubbutat MH. Jones SN, Vousden KH. Regulation of p53 stability by mdm2. Nature 1997; 387: 299-303.
24. Haupt Y, Maya R, Kazaz A, Oren M. mdm2 promotes the rapid degradation of p53. Mature 1997; 387: 296-299.
25. Lane DP, Hall PA. MDM2: arbiter of p53's destruction. Trends Bim-htm Sei. 1997; 22: 372-374.
26. Midgley CA, Lane DP. p53 dependent stability in tumour cells is n M determined by mutation but is dependent on mdm2 binding. Oncogene. ( n press).
27. Schlot! T. Reimer S. Jahns A, et al. Point mutations and nucleotic e insertions in thé mdm2 zinc finger structure of human tumours. J Patlvil 1997: 182: 54-61.
28. Bouger A. Bottger V, Garcia-Echeverria C. et al. Molecular characterization of the mdm2-p53 interaction. J Mol Biol 1997; 269: 744-756.
29. Elenbaas B, Dobbelstcin M, Roth J, Shenk T, Levine AJ. The MDV2 oncoprotein binds specifically to RNA through its ring finger domain. M'tl Meil 1996; 2: 439 451.
30. Shvarts A, Steegenga WT, Riteco N, et al. MDMX: as novel p53-bindh g protein with some functional properties of MDM2. EMBO J 1996; 15: 5349-5357.
31. Lundgren K. Montes de Oca Luna R. McNeill YB. et al. Targetsd expression of MDM2 uncouples S phase from mitosis and inhibits manmary gland development independent of p53. Genes Der 1997; 11: 714-725.
32. Dazard J-E, Augias D, Neel H. et al MDM-2 protein is expressed n different layers of normal human skin. Oncogene 1997: 14: 1123-1128.
33. Kaghad M. Bonnet H. Yang A, et al. Monoallelically expressed gene relattd to p53 at Ip36, a region frequently deleted in neuroblastoma and otli:r human cancers. Cell 1997; 90: 809-819.
34. Schmale H, Bamburger C. A novel protein with strong homology to tl e tumour suppressor p53. Oncogene 1997; 15: 1363-1367.
35. Jost CA. Marin MC. Kaelin WG Jr. p73 is a human p53 related protein th.it can induce apoptosis. Nature 1997; 389: 191-194.